Neonatal bacillus Calmette|[ndash]|Gu|[eacute]|rin vaccination inhibits de novo allergic inflammatory response in mice via alteration of CD4+CD25+ T-regulatory cells
Qian Li,Hua-hao Shen
DOI: https://doi.org/10.1038/aps.2008.3
IF: 7.169
2009-01-01
Acta Pharmacologica Sinica
Abstract:Allergic asthma is a chronic inflammatory disease characterized by reversible airway obstruction, airway hyperreactivity, airway infiltration by inflammatory cells — particularly eosinophils and T lymphocytes — and high levels of allergen-specific immunoglobulin (Ig)E1, 2, 3. Although current asthma therapy is effective and well-tolerated in most patients4, these drugs do not change the underlying immunological mechanisms, and there is a clear medical need for the development of new therapies capable of changing or reprogramming the underlying immune processes to produce a long-term protective immune response. Epidemiological and clinical studies have provided compelling evidence that suggest a link between the relative lack of infectious diseases and the increase in allergic disorders. It has been demonstrated that a positive tuberculin test result suggestive of past infections with mycobacterium tuberculosis was inversely related to the subsequent development of atopy and asthma5. Several animal studies showed that vaccination with mycobacteria prevented asthma development or treated asthmatic manifestations6, 7, 8, 9. However, the mechanism by which mycobacteria inhibits the inflammatory response remains unclear. Induction of Th1 cytokines, such as interferon-γ (IFN-γ), and thus reversion of the imbalance between Th1/Th2, has been proposed7, 8. However, Zuany-Amorim demonstrated that mycobacterium vaccae blocked allergic inflammation by a mechanism independent of IFN-γ9. Our previous study also demonstrated that the neonatal bacille Calmette–Guérin (BCG) vaccination significantly inhibited allergic inflammation, but did not significantly change IFN-γ, interleukin (IL)-4, and IL-5 responses in late-challenged mice10. We thought that mechanisms other than simple changes in the balance between Th1 and Th2 may account for the observed effects of vaccination with mycobacteria. T regulatory (Treg) cells are thought to be the crucial immunoregulatory cells that are capable of suppressing adaptive immune responses. CD4+CD25+ Treg cells are a distinct population of CD4+ Treg cells that constitutively express CD25, with suppressive properties inhibiting the functions of effector CD4+ and CD8+ T cells11, 12, 13. Foxp3 is a master gene governing the development and function of Treg cells14, 15. The suppressive mechanisms of CD4+CD25+ Treg cells are not clear, but there is evidence that cell–cell contact by cytotoxic lymphocyte associated antigen (CTLA)-4 is required16. There is growing and conflicting evidence concerning the roles of IL-10 and transforming growth factor (TGF)-β17, 18. A number of studies have shown that CD4+CD25+ Treg cells play an essential role in limiting the development of immune response in allergy and asthma19, 20, 21. Therapeutic opportunities to exploit the immunosuppressive effects of Treg cells for prophylactic or therapeutic treatment may become feasible. Treg cells may be involved in the inhibitory effect of BCG upon asthma inflammatory response. Vaccination with mycobacteria is associated with persistent chronic intracellular infection in vivo that maintains a sustained immune response. The immune system has regulatory mechanisms for suppressing the effector response to persistent infection. It has been demonstrated that tuberculosis (TB) infection and the BCG vaccination induced increased Foxp3 expression and CD4+CD25+ Treg cells in human peripheral blood22, 23, 24. Given the role of Treg cells in asthma and the effect of mycobacteria infection on Treg cells, we conducted this study to investigate whether the protective effects on allergic pulmonary inflammation of the BCG vaccination are associated with the alteration of CD4+CD25+ Treg cells in a murine asthma model and the mechanisms of Treg cells. The transcription factor Foxp3 that is specifically confined to CD4+CD25+ Treg cells25 was used as a definitive marker for Treg cells. The relative level of Foxp3 mRNA was assessed by RT-PCR in mouse spleens. The relative level of Foxp3 mRNA in the mouse spleens was 0.60±0.18 in the BCG-treated group, 0.38±0.11 in the OVA group, and 0.23±0.12 in the control group, respectively. Consistent with the increased percentage of CD4+CD25+ T cells, there was a significant 1.6-fold increase in the Foxp3 mRNA expression in the mouse spleens of the BCG-treated group compared with the OVA group (P=0.000), and a 2.7-fold increase compared with the control group (P=0.000). There was also a significant increase in the OVA group compared with control group (P=0.011; Figure 3A). The Foxp3 protein expression was also determined. Parallel with the mRNA level, the Foxp3 protein was also upregulated in the mouse spleens of the BCG-treated group compared with the OVA group (P<0.05) and the control group (P<0.05). There was also a significant increase in the OVA group compared with control group (P<0.05, Figure 3B). The present study demonstrates that a neonatal subcutaneously injection of BCG can prevent the development of de novo allergen-induced bronchial inflammation in a murine model of allergic pulmonary inflammation. The reduction of the allergic response was associated with an induction of CD4+CD25+ Treg cells and Foxp3 expression. The cell–cell contact inhibition and regulatory cytokine production may be involved in the regulatory mechanism. In this study, we selected C57BL/6 mice as the animal model. Previous studies reported that BALB/c mice were more prone to a Th2 allergic response than C57BL/6 mice. However, C57BL/6 mice were also selected to make asthma models and used in a series of studies on asthma in our laboratory and those of others10, 26, 27. In this study, the asthma model was proven to be successful based on the eosinophil accumulation in the airway and peribronchial/perivascular tissue pathology. An inverse relationship between the reduced incidence of infection and increased allergy has been observed in the worldwide over the past 2–3 decades, which has led to the “hygiene hypothesis”, that is, that the existence of microbial infections may prevent or inhibit the development of allergic diseases28, 29. Consistent with previous studies6, 7, 8, 9, this experiment suggests that the neonatal BCG vaccination can inhibit the development of a de novo allergic response characterized by a significant reduction of local eosinophilic inflammation. Also, in the previous study10, we investigated the effects of neonatal BCG treatment on allergic inflammation in mice of different ages and found that BCG treatment could attenuate airway hyperresponsiveness and eosinophilia not only in early-challenged (9 weeks age) mice, but also in late-challenged (45 weeks age) mice. We concluded that the neonatal BCG vaccination had a long-term effect on inhibiting airway allergic inflammation. However, the mechanism by which BCG inhibits the inflammatory response is debatable. The induction of Th1 cytokines, such as IFN-γ, and thus the reversion of the imbalance between Th1/Th2, has been proposed7, 8. It has been shown that repeated BCG vaccinations improve lung function and increase the IFN-γ/IL-4 ratio in the peripheral blood in asthmatic patients30. Similarly, our previous study demonstrated that the neonatal BCG vaccination induces a strong Th1 type response, which downregulated allergen-specific Th2 responses in an early-challenged asthmatic model. Surprisingly, we found that the neonatal BCG vaccination significantly inhibited allergic inflammation, but did not significantly change IFN-γ, IL-4, and IL-5 responses in late-challenged mice10. Zuany-Amorim demonstrated that mycobacterium vaccae was effective in blocking allergic inflammation by a mechanism independent of IFN-γ9. The mechanisms other than simple changes in the balance between Th1 and Th2 must be at play. A novel finding in this study is that the neonatal BCG vaccination gives rise to CD4+CD25+ Treg cells and Foxp3 expression in the experimental asthma mice. CD4+CD25+ cells represent 5%–10% of periphery CD4+ T cells, expressing CD25, the IL-2 receptor α-chain11. However, because CD25 is also a marker of activation of T cells, its specificity as a marker of Treg is limited. Foxp3 is a master gene governing the development and function of Treg cells14, 15, and Foxp3 expression distinguishes Treg from activated effector cells within the CD25+ T-cell population31. Thus the Foxp3 expression is considered to be the most definite marker of Treg cell activity. We demonstrated that the increases in both the cell surface CD25 expression and Foxp3 expression were the 2 most accurate available markers for the activation of Treg. Therefore, we can conclude that the neonatal BCG vaccination induces the increase of CD4+CD25+ Treg cells in mice. The 3 BCG vaccinations induced a systemic infection in the mice, and the immune responses were not limited to a regional lymph node. The spleen is the important peripheral lymph organ and abundant in lymphocytes. It plays a key role in the immune response to BCG. The tissue order of the proportion of CD4+CD25+/CD4+ T cells from high to low is spleen, lymph node, peripheral blood, and thymus. The total number of CD4+CD25+ Treg cells in 1 mouse lung is approximately 5×104–7×104 after being intranasally infected with BCG32. The low number of Treg cells can not ensure stable experiment results. Considering all the facts, we selected the spleen as our target tissue. The BCG vaccination is associated with persistent antigen stimulation and chronic infection in vivo. Many pathogens that cause persistent or chronic infections have evolved strategies to subvert the immune responses of the host. One important immune-subversion strategy is the generation of Treg cells. A number of bacterial, viral, and protozoal infections have been shown to maintain the involvement of CD4+CD25+ Treg cells, such as Leishmania major17, Plasmodium yoeli33, polymicrobial sepsis34, and hepatitis C35. Treg cells are activated by infections. Microbial products can evolve to favor Treg cells' priming, recruitment, and survival. Regarding mycobacteria infection, Guyot-Revol found that in patients with TB, percentages of CD4+CD25 high T cells and levels of Foxp3 mRNA expression in peripheral blood mononuclear cells were both significantly higher compared with controls22. In blood samples from 5675 10-week-old South African infants routinely vaccinated with BCG at birth, the Foxp3 mRNA expression is inducted, which suggests the presence of BCG-induced CD4+ Treg cells23. CD4+CD25 high Foxp3+ Treg cells can be expanded or induced in the peripheral blood of mycobacterium tuberculosis latently infected individuals in conditions known to be predisposed to progression towards active tuberculosis and may therefore play an important role in the pathogenesis of the disease24. Once activated by the antigen-specific stimulation via the T-cell receptor, CD4+CD25+ cells can suppress the activation and proliferation of other effector CD4+ and CD8+ T cells. The suppression acts in an Ag-non-specific bystander manner36, 37, 38. Allergic asthma is characterized by inflammation mediated by CD4+ Th2 cells. CD4+CD25+ T cells can suppress Th2 maturation39, possibly by inhibiting IL-4 production40. Jaffar demonstrated that CD4+CD25+ T cells limited the development of a CD4+ Th2 phenotype by reduced cytokine production41. There is increasing evidence that Treg play an essential role in limiting the development of immune response in allergy and asthma. It has been shown that CD4+CD25+ Treg cells isolated from hay fever patients have an impaired ability to suppress proliferation and IL-5 production of CD4+CD25– T cells compared with healthy controls19. Lewkowich et al. used an anti-CD25 antibody to deplete CD25+ cells in vivo and showed that the depletion of CD25+ cells before delivery of a house dust mite allergen led to significantly increased Th2 cytokine responses, IgE levels, eosinophilia, and allergen-induced airway hyperresponsiveness (AHR) in allergy-resistant mice20. Using a complementary approach, Kearley et al transferred Treg cells to the immunocompetent mice previously sensitized with OVA and thus inhibited AHR, eosinophil recruitment, and Th2 cytokine production21. Collectively, we speculated that the activated CD4+CD25+ Treg cells by BCG vaccination suppressed the polarized Th2 response in the asthma mice and thus inhibited the allergic inflammatory response. The mechanism of the suppressive function of Treg cells is still unclear. Suppressive activity has been shown to be mediated through cell–cell contact essentially42 or through secretion of immunosuppressive cytokines equivocally. Cell–cell contact is mediated by CTLA-4 expressed by CD4+CD25+ Treg cells, which interacts with CD80 and/or CD86 on the surface of antigen-presenting cells (APC). This interaction delivers a negative signal for effector T-cell activation16. Read et al found that the blockade of CTLA-4 on CD4+CD25+ Treg cells abrogated their function in vivo43. Our data demonstrate that the CTLA-4 mRNA expression was increased in the spleens of the BCG-treated mice. Although CTLA-4 is not absolutely expressed on Treg, considering the activation of Treg and the essential role of CTLA-4 in the suppressive mechanism, we can reason that the suppressive effects of the activated Treg were at least partially conducted through cell–cell contact mediated by CTLA-4. Transwell experiments are needed to definitely elucidate whether direct cell–cell contact is required and whether CTLA-4 actually works. In the present study, we demonstrate that cultures of splenocytes from BCG-treated mice contain significantly higher levels of IL-10 and TGF-β compared with that in OVA and control mice. The production of IL-1044 and TGF-β45 have been shown to be required in the suppression of effector T cells by CD4+CD25+ T cells. In allergies, IL-10 and TGF-β skew the production of IgE towards non-inflammatory isotypes IgG4 and IgA, respectively46, 47. However, most studies suggest that CD4+CD25+ Treg cells are not major producers of IL-10 and TGF-β48. Pathogens have been shown to induce the production of either one or both of these cytokines by immature or semimature APC and dendritic cells (DC), and to facilitate the induction of aTreg cells in this way49, 50. CD4+CD25+ Treg cells were also found to aid the generation of aTreg that mediated suppression by these cytokines51, 52. Taken together, we hypothesized that the involvement of the inhibitory cytokines in the suppression effect of CD4+CD25+ Treg cells induced by BCG-treatment was indirect. We propose in this study that neonatal repeat BCG vaccinations inhibited the de novo allergic inflammatory response in mice via the alteration of the CD4+CD25+ Treg cell pathway. It is interesting to further investigate other immunoregulatory mechanisms that underlie the inhibitory effects of BCG vaccinations. We also examined the contents of IL-5, IL-13, and IL-17E in BALF by ELISA10 and found that higher levels of IL-5 were observed in the BALF of mice in the OVA group while the levels of IL-5 in the BCG group were greatly reduced. Furthermore, low levels of IL-13 and IL-17E were detected from different groups of mice, but were indistinguishable among these groups. These data were consistent with the conclusion and suggested IL-13 and IL-17E may be not involved in the protection of BCG treatment in our experimental models, although they have been shown to be crucial for asthmatic inflammation in other experimental models. In this study, we propose that neonatal BCG vaccinations ameliorate de novo local eosinophilic inflammation induced by allergens and increase the numbers of CD4+CD25+ Treg cells and Foxp3 expression. The cell–cell contact inhibition and regulatory cytokine production may be involved in the regulatory mechanism. Hua-hao SHEN designed research; Qian LI performed research; Qian LI contributed new analytical tools and reagents; Hua-hao SHEN analyzed data; Qian LI and Hua-hao SHEN wrote the paper. Project supported by the key programs of the Ministry of Health (WKJ2005-2-039), the key programs of Natural Science Foundation of Zhejiang Province in China (No 2007C24012) and High-level Innovation Personnel Project of Department of Health of Zhejiang Province, China to Hua-hao SHEN.